Please ensure Javascript is enabled for purposes of website accessibility

Novavax Raising $200 Million to Fund Coronavirus and Flu Vaccine Efforts

By Keith Speights – Jun 15, 2020 at 11:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is selling convertible preferred stock through a private placement deal with RA Capital Management.

Novavax (NVAX -8.09%) announced on Monday that it plans to raise around $200 million through a private placement with RA Capital Management. An investment fund affiliated with RA Capital will purchase a quantity of Series A Convertible preferred stock from Novavax that is convertible into 4,388,852 shares of common stock.

The biotech intends to use the additional capital to help fund its development of a COVID-19 vaccine candidate and to advance its U.S. regulatory filing for approval of flu vaccine NanoFlu. CEO Stanley C. Erck stated that Novavax believes that the RA Capital transaction "signals a high level of confidence in the significant progress of our COVID-19 and influenza vaccine programs."

Gloved hands holding syringe and vaccine bottle

Image source: Getty Images.

RA Capital Management Managing Partner Peter Kolchinsky supported Erck's take, and particularly noted that the investment "will support Novavax in its important work developing an effective, scalable vaccine for SARS-CoV-2."

The private placement will bolster Novavax's cash position, which as of March 31 was $244.7 million, including cash, cash equivalents, marketable securities, and restricted cash. In May, the company announced that it will receive up to $384 million in additional funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop and manufacture its COVID-19 vaccine candidate. Novavax has already used some of its cash to acquire Czech-based Praha Vaccines to boost its COVID-19 vaccine manufacturing capacity.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$17.83 (-8.09%) $-1.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.